ライフサイエンスコーパス: pleural mesothelioma

1 f disease in patients with diffuse malignant pleural mesothelioma.

2 in the palliation of patients with malignant pleural mesothelioma.

3 e or placebo in patients with nonepithelioid pleural mesothelioma.

4 tedanib or placebo in unresectable malignant pleural mesothelioma.

5 exist for second-line treatment of malignant pleural mesothelioma.

6 in relapsed mesothelin-expressing malignant pleural mesothelioma.

7 ents with previously untreated, unresectable pleural mesothelioma.

8 heckpoint therapy is now standard of care in pleural mesothelioma.

9 fety profile in patients with nonepithelioid pleural mesothelioma.

10 ovement in overall survival in patients with pleural mesothelioma.

11 the complex genomic background of malignant pleural mesothelioma.

12 ed 68 with advanced ASS1-deficient malignant pleural mesothelioma.

13 ent option for previously untreated advanced pleural mesothelioma.

14 nds) as maintenance therapy in patients with pleural mesothelioma.

15 measurable relapsed or refractory malignant pleural mesothelioma.

16 ld improve overall survival in patients with pleural mesothelioma.

17 ty in patients with PD-L1-positive malignant pleural mesothelioma.

18 on in patients with ASS1-deficient malignant pleural mesothelioma.

19 therapy for patients with advanced malignant pleural mesothelioma.

20 talc pleurodesis in patients with malignant pleural mesothelioma.

21 os and silica seemed to increase the risk of pleural mesothelioma.

22 e treatment of recurrent and/or unresectable pleural mesothelioma.

23 best available serum biomarker of malignant pleural mesothelioma.

24 rol groups and 1,026 patients with malignant pleural mesothelioma.

25 e of action for asbestos in the induction of pleural mesothelioma.

26 modality therapy in stage I to III malignant pleural mesothelioma.

27 apeutic option in the treatment of malignant pleural mesothelioma.

28 estos and 76 patients with surgically staged pleural mesothelioma.

29 ng of the tumor cells in 36 of 38 samples of pleural mesothelioma.

30 rom those with exposure to asbestos who have pleural mesothelioma.

31 h cisplatin alone in patients with malignant pleural mesothelioma.

32 ing CD8+ T cells in malignant peritoneal and pleural mesotheliomas.

33 d were significantly higher in patients with pleural mesothelioma (105+/-7 ng per milliliter in the D

34 s were significantly higher in patients with pleural mesothelioma (694+/-37 ng per milliliter in the

35 Patients with malignant pleural mesothelioma, a rapidly progressing malignancy w

36 s with histologically confirmed unresectable pleural mesothelioma, aged 18 years or older, with an Ea

37 ble locally advanced or metastatic malignant pleural mesothelioma, an Eastern Cooperative Oncology Gr

38 investigated the presence of osteopontin in pleural mesothelioma and determined serum osteopontin le

39 Patients with measurable advanced malignant pleural mesothelioma and disease progression after one o

40 ars) with unresectable epithelioid malignant pleural mesothelioma and ECOG performance status 0-1 wer

41 dality therapy in the treatment of malignant pleural mesothelioma and identify prognostic factors.

42 h cisplatin is approved for the treatment of pleural mesothelioma and is active in malignant peritone

43 engineering strategy in a model of malignant pleural mesothelioma and validate our findings in a matc

44 803 cancer-related genes were studied in 158 pleural mesotheliomas and 18 normal pleura.

45 ins contribute to the malignant phenotype of pleural mesotheliomas and indicate that interventions de

46 has been reported in varying proportions of pleural mesotheliomas and other tumours, but data are co

47 eous pneumothorax in patients with malignant pleural mesotheliomas and primary lung tumors, and bilat

48 ients with pleural effusion due to malignant pleural mesothelioma, and talc pleurodesis might be pref

49 Treatment options for malignant pleural mesothelioma are scarce.

50 New biomarkers are needed to detect pleural mesothelioma at an earlier stage and to individu

51 The successful treatment of unresectable pleural mesothelioma awaits the discovery of active drug

52 rkers for tazemetostat activity in malignant pleural mesothelioma beyond BAP1 inactivation could help

53 Pembrolizumab has activity in diffuse pleural mesothelioma but limited data are available for

54 type I IGF receptor in a subset of malignant pleural mesothelioma cell lines and determined the corre

55 ere, we report the data of a large malignant pleural mesothelioma cohort within a (68)Ga-FAPI46 PET o

56 ere on the interim analysis of the malignant pleural mesothelioma cohort.

57 , every 3 wk) for the treatment of malignant pleural mesothelioma did not result in survival benefit

58 y approved first-line treatments for diffuse pleural mesothelioma (DPM) are ipilimumab-nivolumab or p

59 n diverse cancer types, notably in malignant pleural mesothelioma (DPM), and has also been identified

60 ICB) is standard of care in advanced diffuse pleural mesothelioma (DPM), but its role in the perioper

61 results are in favor of an increased risk of pleural mesothelioma for subjects exposed to both asbest

62 ients with chemotherapy-naive nonepithelioid pleural mesothelioma from August 1, 2017, to August 15,

63 409 patients with malignant pleural mesothelioma, from 76 centres in the UK and two

64 d quality of life in patients with malignant pleural mesothelioma have, to our knowledge, not been as

65 Methods: Human pleural mesothelioma (I45) and ovarian adenocarcinoma (S

66 ctive review of patients with a diagnosis of pleural mesothelioma in the period 2019-2021, analysing

67 ally, the presence of both mutations induced pleural mesotheliomas in 23% of these mice.

68 d Affymetrix U133A microarray analysis on 99 pleural mesotheliomas, in which multivariate analysis sh

69 Malignant pleural mesothelioma incidence continues to rise, with f

70 literature of clinical studies in malignant pleural mesothelioma, including phase II trials of the n

71 Malignant pleural mesothelioma is a highly aggressive cancer with

72 Malignant pleural mesothelioma is a relatively uncommon and yet in

73 Malignant pleural mesothelioma is almost always fatal, and few tre

74 Malignant pleural mesothelioma is an aggressive malignancy charact

75 Pleural mesothelioma is an aggressive malignancy with li

76 Malignant pleural mesothelioma is an aggressive primary neoplasm f

77 edition of the TNM staging classification of pleural mesothelioma is an update in the TNM staging, re

78 sed immunotherapy in patients with malignant pleural mesothelioma is feasible, well-tolerated, and ca

79 The incidence of malignant pleural mesothelioma is increasing throughout most of th

80 As pleural mesothelioma is known to have limited numbers of

81 al from malignant mesothelioma, particularly pleural mesothelioma, is very poor.

82 eadily detected in genomic DNA isolated from pleural mesothelioma lines; however, levels of SV40 T/t

83 ype was highly significant for patients with pleural mesothelioma (median survival 7.9 y versus 2.4 y

84 ishevelled (Dvl) overexpression in malignant pleural mesothelioma (MM).

85 y proposed frontline therapies for malignant pleural mesothelioma (MPM) are very costly, yet their im

86 Malignant pleural mesothelioma (MPM) carries a poor prognosis due

87 malignant mesothelial tissues and malignant pleural mesothelioma (MPM) cell lines as compared to ben

88 r TTFields, we applied TTFields to malignant pleural mesothelioma (MPM) cells forming TNTs in vitro.

89 in paraffin tumor tissues such as malignant pleural mesothelioma (MPM) could yield insights to actio

90 Malignant pleural mesothelioma (MPM) expresses high levels of epid

91 Malignant pleural mesothelioma (MPM) has an overall poor prognosis

92 peutic procedures in patients with malignant pleural mesothelioma (MPM) has been a widespread practic

93 ion of the genomic complexities of malignant pleural mesothelioma (MPM) has lagged behind other malig

94 Malignant pleural mesothelioma (MPM) has relatively ineffective fi

95 Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemothe

96 Malignant pleural mesothelioma (MPM) is a deadly disease that occu

97 Malignant pleural mesothelioma (MPM) is a disease of increasing in

98 Malignant pleural mesothelioma (MPM) is a highly aggressive and ge

99 Malignant pleural mesothelioma (MPM) is a highly aggressive tumor

100 Malignant pleural mesothelioma (MPM) is a highly lethal, poorly un

101 Malignant pleural mesothelioma (MPM) is a rare malignancy with few

102 Malignant pleural mesothelioma (MPM) is a rare malignancy with no

103 Malignant pleural mesothelioma (MPM) is a rare, aggressive, and in

104 Malignant pleural mesothelioma (MPM) is a rare, but aggressive tum

105 Malignant pleural mesothelioma (MPM) is an aggressive cancer that

106 Malignant pleural mesothelioma (MPM) is an aggressive cancer that

107 Malignant pleural mesothelioma (MPM) is an aggressive cancer with

108 Malignant pleural mesothelioma (MPM) is an aggressive human cancer

109 Malignant pleural mesothelioma (MPM) is an aggressive malignancy a

110 Malignant pleural mesothelioma (MPM) is an aggressive neoplasm ass

111 Malignant pleural mesothelioma (MPM) is an aggressive thoracic can

112 Human malignant pleural mesothelioma (MPM) is considered a rare tumor, b

113 Hemithoracic IMPRINT for malignant pleural mesothelioma (MPM) is safe and has an acceptable

114 Malignant Pleural Mesothelioma (MPM) is typically diagnosed 20-50

115 ed in patients with ASS1-deficient malignant pleural mesothelioma (MPM) or non-small-cell lung cancer

116 Outcomes of localized malignant pleural mesothelioma (MPM) remain poor despite multimoda

117 ry (LA-ICP-TOFMS) to analyze human malignant pleural mesothelioma (MPM) samples at the cellular level

118 targeted exomes (n = 103) from 216 malignant pleural mesothelioma (MPM) tumors.

119 ned and tested in 28 patients with malignant pleural mesothelioma (MPM) who underwent lung MRI to dem

120 Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (Onconase) re

121 tor-1 (PAR1, F2R) on the growth of malignant pleural mesothelioma (MPM), using human MPM cells that l

122 In Malignant Pleural Mesothelioma (MPM), YAP is activated by loss-of-

123 ation exclusively in patients with malignant pleural mesothelioma (MPM).

124 re to FE fibers is correlated with malignant pleural mesothelioma (MPM).

125 therapy as first-line treatment of malignant pleural mesothelioma (MPM).

126 rapy in patients with unresectable malignant pleural mesothelioma (MPM).

127 burden over time in patients with malignant pleural mesothelioma (MPM).

128 MTAP) deletion, seen frequently in malignant pleural mesothelioma (MPM).

129 ured tumor volume in patients with malignant pleural mesothelioma (MPM).

130 P) in the treatment of epithelioid malignant pleural mesothelioma (MPM).

131 y in the treatment of unresectable malignant pleural mesothelioma (MPM).

132 bine have single-agent activity in malignant pleural mesothelioma (MPM).

133 as not been extensively studied in malignant pleural mesothelioma (MPM).

134 rgoing cancer-directed surgery for malignant pleural mesothelioma (MPM); however, it is unclear if th

135 e pathological distinction between malignant pleural mesothelioma (MPM)and adenocarcinoma (ADCA) of t

136 en shown to be highly expressed in malignant pleural mesotheliomas (MPM), was detected in serum using

137 l-cell lung cancer (NSCLC), and 71 malignant pleural mesotheliomas (MPM).

138 ns and expression levels unique to malignant pleural mesotheliomas (MPMs) and not present in control

139 Malignant pleural mesotheliomas (MPMs) often show CDKN2A and NF2 i

140 oncoproteins have been detected in malignant pleural mesotheliomas (MPMs), their role in the pathogen

141 Treatment of human pleural mesothelioma (MS-1) cells with phorbol myristate

142 DNA methylation profiles in a case series of pleural mesotheliomas (n = 23).

143 s were aged 18 years or older with malignant pleural mesothelioma of any histology that was relapsed

144 ria In Solid Tumors (RECIST) version 1.0 for pleural mesothelioma or RECIST version 1.1 for peritonea

145 nases, which are all implicated in malignant pleural mesothelioma pathogenesis.

146 sease) at week 12 in patients with malignant pleural mesothelioma per protocol with BAP1 inactivation

147 a major barrier for long-term survival after pleural mesothelioma (PM) surgery.

148 hemotherapy and prophylactic radiotherapy in pleural mesothelioma (PM).

149 Ten patients with malignant pleural mesothelioma received metronomic cyclophosphamid

150 ocedure-tract metastases (PTMs) in malignant pleural mesothelioma remains controversial, and clinical

151 effective treatments, survival from diffuse pleural mesothelioma remains poor.

152 ur previous microarray analysis of malignant pleural mesothelioma revealed alterations in components

153 surgically resected lung adenocarcinoma and pleural mesothelioma samples in tissue microarrays to co

154 ling pathways of the IGF system in malignant pleural mesothelioma specimens.

155 were significantly higher in the group with pleural mesothelioma than in the group with exposure to

156 In thoracic cancer (lung cancer and pleural mesothelioma), the univariate and multivariate a

157 In patients with advanced pleural mesothelioma, the addition of pembrolizumab to s

158 system components represent novel malignant pleural mesothelioma therapeutic targets for investigati

159 port on their use of a murine model of human pleural mesothelioma to explore potential factors that l

160 benefit reported in patients with malignant pleural mesothelioma treated in a phase 1 study of vorin

161 In patients with pleural mesothelioma treated with ICB, triads are associ

162 le mechanisms likely contribute to malignant pleural mesothelioma tumorigenesis.

163 vel of 1% or higher, small cell lung cancer, pleural mesothelioma, urothelial carcinoma, esophagogast

164 (18)F-FDG-CI in the assessment of malignant pleural mesothelioma using histopathology as the gold st

165 Pleural mesothelioma usually presents at an advanced, in

166 in patients with BAP1-inactivated malignant pleural mesothelioma was 54% (95% CI 42-67; 33 of 61 pat

167 Using an orthotopic mouse model of pleural mesothelioma, we determined that relatively high

168 atients with histologically proven malignant pleural mesothelioma were enrolled (26 male patients and

169 eated patients with PD-L1-positive malignant pleural mesothelioma were enrolled from 13 centres in si

170 ts (cohort 1, n = 56; cohort 2, n = 52) with pleural mesothelioma were enrolled.

171 ears; 10 women and 29 men) with unresectable pleural mesothelioma were treated with repetitive transa

172 e not exposed to asbestos, and patients with pleural mesothelioma who were exposed to asbestos.

173 Patients with pleural mesothelioma with inherited mutations in DNA rep

174 spite several attempts at treating malignant pleural mesothelioma with various modalities, mortality

175 or older, with previously untreated advanced pleural mesothelioma, with an Eastern Cooperative Oncolo

176 Our data suggest that in malignant pleural mesothelioma, Wnt signaling is activated through